Bis-THF Alcohol CAS 156928-09-5: Applications, Demand and Development Outlook
Explore Rlavie bis-THF alcohol CAS 156928-09-5 for protease-inhibitor route research and process development.
Chiral bis-THF alcohol (CAS 156928-09-5), also named (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol, gives process chemists access to a compact building block with three defined stereocentres. Rlavie lists this material for research and development enquiries involving protease-inhibitor chemistry.
Established applications and customer value
The Ireland EPA process document listed below identifies this CAS number among materials used in disclosed darunavir processing. It supports the compound’s route relevance, while leaving commercial supplier relationships unestablished. Research teams can evaluate the building block in activation and coupling studies, route comparison, impurity investigations and analytical-method development. Purchasing a characterized advanced fragment may reduce the upstream work needed for those projects.
Market context and development outlook
EMA identifies Darunavir Viatris as a generic medicine. This gives a concrete example of lifecycle activity around an established antiviral ingredient. For intermediate buyers, the practical opportunity is in process evaluation, reproducibility and alternative-source qualification. These are potential project needs, not a quantified forecast of demand for this building block.
Quality requirements that support purchasing decisions
A useful sourcing discussion covers structure confirmation, absolute configuration, enantiomeric and diastereomeric composition, assay, water and residual solvents. Because multiple stereocentres are present, chemical purity alone cannot describe the full stereochemical profile. ICH Q11 provides the broader pharmaceutical framework for linking material attributes and impurity fate to a control strategy.
Discuss your project with Rlavie
Send the required quantity, intended research use and target specifications to Rlavie to discuss available documentation, packaging and lead time. Confirm batch-specific suitability before incorporating the material into a development programme.
Related Rlavie products
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
- Ireland EPA: disclosed darunavir process materials
- EMA Darunavir Viatris: generic medicine and regulatory context
- ICH Q11: process development and control strategy
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.